Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5422605 | 0.92 | ESR1 (0.68) | ESR2ESR1 | |
| SCHEMBL5420001 | 0.90 | ESR1 (0.69) | ESR2ESR1 | |
| SCHEMBL5432545 | 0.88 | ESR2 (0.67) | ESR2ESR1 | |
| SCHEMBL5422950 | 0.87 | ESR2 (0.67) | ESR2ESR1 | |
| SCHEMBL5426409 | 0.85 | ESR2 (0.68) | ESR2ESR1 | |
| SCHEMBL5430051 | 0.84 | ESR2 (0.69) | ESR2ESR1 | |
| SCHEMBL5428916 | 0.83 | ESR2 (0.69) | ESR2ESR1 | |
| SCHEMBL5426298 | 0.83 | ESR2 (0.55) | ESR2ESR1 | |
| SCHEMBL5423825 | 0.83 | ESR2 (0.67) | ESR2ESR1 | |
| SCHEMBL5421092 | 0.82 | ESR2 (0.70) | ESR2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191438-A1 | Methods for the treatment of hypertension | ROHRER SUSAN P | 2007-08-16 | — | — | US | claimed |
| EP-1339683-B1 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2006-06-14 | — | — | EP | claimed |
| US-20070191438-A1 | Methods for the treatment of hypertension | ROHRER SUSAN P | 2007-08-16 | — | — | US | disclosed |
| EP-1339683-B1 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2006-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191438-A1 | Methods for the treatment of hypertension | EDNRA, GPER1, EDNRB | ESR2 8/4885ESR1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.